CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 6 incoming connections
- ScaleRevenue is $769.19M, above the global median of $562.3M
- PositionProfit margin is -4.6%, lower than 95% of its Pharmaceutical Retailers peers (median 1.7%)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.46%Above 5Y avg (0.31%)
Annual Rate
CNY 0.04Paid semi-annual
Payout Ratio
66.7%Moderate
Payback Period
83.7 yr
Last Ex-Dividend
Dec 15, 2025
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.98BCNY296.77M · vs all stocks (USD)
Revenue (TTM)
5.14BCNY769.19M · vs all stocks (USD)
Profit Margin
-4.59%vs Pharmaceutical Retailers peers
Beta
0.6260xvs all stocks
52-Week Change
-19.65%vs all stocks
Forward Annual Dividend Yield
0.46%vs all stocks
Market Capitalization
1.98BCNY296.77M · vs all stocks (USD)
Enterprise Value
5.10BCNY763.67M · vs all stocks (USD)
Price to Sales (TTM)
0.3878xvs Pharmaceutical Retailers peers
Price to Book (MRQ)
1.33xvs Pharmaceutical Retailers peers
Enterprise to Revenue
0.9930xvs Pharmaceutical Retailers peers
Enterprise to EBITDA
29.41xvs Pharmaceutical Retailers peers
Gross Margin
19.43%vs Pharmaceutical Retailers peers
Profit Margin
-4.59%vs Pharmaceutical Retailers peers
Operating Margin
3.91%vs Pharmaceutical Retailers peers
Return on Assets (TTM)
0.99%vs Pharmaceutical Retailers peers
Return on Equity (TTM)
-12.71%vs Pharmaceutical Retailers peers
Revenue (TTM)
5.14BCNY769.19M · vs all stocks (USD)
Revenue per Share (TTM)
27.85CNYUpdated Oct 21, 2026Quarterly Revenue Growth
-6.50%vs Pharmaceutical Retailers peers
Gross Profit (TTM)
979.32MCNY146.62M · vs all stocks (USD)
EBITDA (TTM)
251.11MCNY37.60M · vs all stocks (USD)
Net Income (TTM)
-236.10MCNY-35.35M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
1.36%vs Pharmaceutical Retailers peers
Operating Cash Flow (TTM)
17.79MCNY2.66M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
171.52MCNY25.68M · vs all stocks (USD)
Forward Annual Dividend Rate
0.0440CNYUpdated Oct 21, 2026Forward Annual Dividend Yield
0.46%vs all stocks
Trailing Annual Dividend Rate
0.1038CNYUpdated Oct 21, 2026Trailing Annual Dividend Yield
1.08%vs all stocks
5-Year Average Dividend Yield
0.31%vs all stocks
Payout Ratio
66.67%vs Pharmaceutical Retailers peers
Minority Interest (Equity)
105.08MCNYFY2025 · Dec 31, 2025Revenue
5.14BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
4.21BCNYFY2025 · Dec 31, 2025Gross Profit
936.34MCNYFY2025 · Dec 31, 2025Operating Income
109.52MCNY16.40M · vs all stocks (USD)
Pre-tax Income
-220.43MCNYFY2025 · Dec 31, 2025Income Tax Expense
8.32MCNYFY2025 · Dec 31, 2025Net Income
-228.75MCNYFY2025 · Dec 31, 2025EBIT
-113.67MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
251.11MCNYFY2025 · Dec 31, 2025Research & Development
11.85MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
239.11MCNYFY2025 · Dec 31, 2025Other Operating Expenses
26.35MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
3.31MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
106.76MCNYFY2025 · Dec 31, 2025EPS (Basic)
-1.18CNYFY2025 · Dec 31, 2025EPS (Diluted)
-1.18CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
205.47MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
205.47MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-228.75MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-13.71MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-544.33MCNYFY2025 · Dec 31, 2025Free Cash Flow
-648.79MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
254.59MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-228.75MCNYFY2025 · Dec 31, 2025Other Non-cash Items
136.30MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-388.47MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-63.41MCNYFY2025 · Dec 31, 2025Capital Expenditures
-104.46MCNYFY2025 · Dec 31, 2025Net Acquisitions
-109.53MCNYFY2025 · Dec 31, 2025Sale of Investments
688.55KCNYFY2025 · Dec 31, 2025Other Investing Activity
-7.52MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-220.81MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
2.66BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-2.49BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-111.99MCNYFY2025 · Dec 31, 2025Other Financing Charges
79.68MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
143.94MCNYFY2025 · Dec 31, 2025Shares Outstanding
205.40MSharesUpdated Oct 21, 2026Float Shares
107.76MSharesUpdated Oct 21, 2026% Held by Insiders
50.69%vs all stocks
% Held by Institutions
9.54%vs all stocks
Total Cash (MRQ)
589.57MCNY88.27M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.87CNYUpdated Oct 21, 2026Total Debt (MRQ)
3.57BCNY535.02M · vs all stocks (USD)
Total Debt to Equity (MRQ)
2.21xvs Pharmaceutical Retailers peers
Current Ratio (MRQ)
1.05xvs Pharmaceutical Retailers peers
Book Value per Share (MRQ)
7.28CNYUpdated Oct 21, 2026Total Assets
6.34BCNY948.77M · vs all stocks (USD)
Total Current Assets
3.97BCNYFY2025 · Dec 31, 2025Total Liabilities
4.74BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.37BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
747.89MCNYFY2025 · Dec 31, 2025Total Current Liabilities
4.00BCNYFY2025 · Dec 31, 2025Cash
247.40MCNYFY2025 · Dec 31, 2025Cash Equivalents
339.33MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
586.73MCNYFY2025 · Dec 31, 2025Other Short-term Investments
9.82MCNYFY2025 · Dec 31, 2025Accounts Receivable
1.95BCNYFY2025 · Dec 31, 2025Inventory
932.63MCNYFY2025 · Dec 31, 2025Accounts Payable
812.65MCNYFY2025 · Dec 31, 2025Short-term Debt
2.95BCNYFY2025 · Dec 31, 2025Other Current Liabilities
3.21MCNYFY2025 · Dec 31, 2025Long-term Debt
722.39MCNYFY2025 · Dec 31, 2025Common Stock (Book)
205.40MCNYFY2025 · Dec 31, 2025Retained Earnings
296.58MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.59BCNY238.50M · vs all stocks (USD)
52-Week Low
7.65CNYUpdated Oct 21, 202652-Week High
14.85CNYUpdated Oct 21, 202652-Week Change
-19.65%vs all stocks
Beta
0.6260xvs all stocks
50-Day MA
10.30CNYUpdated Oct 21, 2026200-Day MA
10.91CNYUpdated Oct 21, 2026Avg 10-Day Volume
3.09MSharesUpdated Oct 21, 2026Avg 30-Day Volume
3.00MSharesUpdated Oct 21, 2026Diluted EPS (TTM)
-1.14CNYUpdated Oct 21, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Within or Near the Altman Distress Zone
Debt is a large share of its assets, and large against its cash flow.
Reads
Elevated Leverage on Three Denominators
Debt sits high against its equity, its assets, and its cash flow.
Reads
Receivables Heavy and Growing
Money owed by customers keeps growing, and is much of its current assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Profit margin is -4.6%, lower than 95% of its Pharmaceutical Retailers peers (median 1.7%)Significant
Profit margin: -0.05Industry median: 0.02Industry P5: -0.04Peers compared: 21.00
Debt-to-equity is 2.21×, higher than 95% of its Pharmaceutical Retailers peers (median 0.68×)Significant
Debt-to-equity: 2.21Industry median: 0.68Industry P95: 1.82Peers compared: 21.00
Financial Health
Altman Z-Score 1.06: distress zoneCritical
Altman Z-Score: 1.06
Low earnings qualitySignificant
Earnings Quality Score: -3.35
Supply Chain
Midstream position: 5 outgoing, 6 incoming connectionsNotable
Outgoing: 5.00Incoming: 6.00
High connectivity hub: 11 industry connectionsNotable
Total Connections: 11.00
Scale
Revenue is $769.19M, above the global median of $562.3MNotable
Revenue (USD): 769,193,576.366Global Median: 562,304,852.367
Levered free cash flow is $25.68M, above the global median of $18.69MNotable
Levered free cash flow (USD): 25,680,614.004Global Median: 18,689,872.41
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai Pioneer Holding Ltd.
Tier 1FlowUnit ReplicationInterfaceRule
Sichuan Hezong Medicine Co., Ltd.
Tier 1FlowUnit ReplicationProductionInterface
Shanghai No.1 Pharmacy Co., Ltd.
Tier 1FlowUnit ReplicationInterfaceRule
EVgo, Inc.
Tier 1FlowUnit ReplicationProductionInterface
CMS Info Systems Ltd.
Tier 1FlowUnit ReplicationProductionRisk
PTG Energy Public Company Limited
Tier 1FlowUnit ReplicationInterfaceProduction
Yunnan Jianzhi Health Chain Co., Ltd.
Tier 1FlowUnit ReplicationInterfaceRule
Beijing Hanbang Technology Co., Ltd.
Tier 1FlowUnit ReplicationProductionRule
Ministop Co., Ltd.
Tier 1FlowUnit ReplicationInterfaceProduction
G-7 Holdings Inc.
Tier 1FlowUnit ReplicationInterfaceProduction
Companies that share active interpretations — structural patterns currently present in both stocks.
Savannah Energy PLC
3 interpretationsWithin or Near the Altman Distress ZoneReceivables Heavy and GrowingElevated Leverage on Three Denominators
Verra Mobility Corporation
3 interpretationsWithin or Near the Altman Distress ZoneReceivables Heavy and GrowingElevated Leverage on Three Denominators
Verizon Communications Inc.
3 interpretationsWithin or Near the Altman Distress ZoneReceivables Heavy and GrowingElevated Leverage on Three Denominators